Therapeutic Efficacy of Ozenoxacin in Animal Models of Dermal Infection with Staphylococcus Aureus | Zendy

Cristina Tarragó | Zendy; Lluís Pérez Esquirol | Zendy; A Arañó | Zendy; Laurence Lachamp | Zendy; Fabiana D’Aniello | Zendy; Ilonka Zsolt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Therapeutic Efficacy of Ozenoxacin in Animal Models of Dermal Infection with Staphylococcus Aureus

Author(s) -

Cristina Tarragó,

Lluís Pérez Esquirol,

A Arañó,

Laurence Lachamp,

Fabiana D’Aniello,

Ilonka Zsolt

Publication year - 2018

Publication title -

future microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.797

H-Index - 82

eISSN - 1746-0921

pISSN - 1746-0913

DOI - 10.2217/fmb-2017-0290

Subject(s) - staphylococcus aureus , microbiology and biotechnology , staphylococcal infections , biology , medicine , virology , bacteria , genetics

Aim: To assess different concentrations and formulations of topical ozenoxacin using a mouse model of Staphylococcus aureus dermal infection for identification of the best formulation for treating patients with impetigo. Materials & methods: The efficacy of ozenoxacin formulations was compared with vehicle control, mupirocin and retapamulin ointments in a mouse model. Results: The most effective concentrations of ozenoxacin for reducing S. aureus counts after dermal application were 1 and 2%. Direct comparison of two batches of 1% ozenoxacin ointment and cream with 1% retapamulin and 2% mupirocin ointments in the mouse model showed superior efficacy of ozenoxacin. Conclusion: 1% ozenoxacin ointment and cream were the most effective formulations in significantly reducing bacterial load in S. aureus dermally infected mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research